Boron carbide (B4C)-reinforced metal matrix composites (MMCs) are promising candidates for biomedical implants due to their mechanical properties and potential biological compatibility. In this study, in vitro biocompatibility and cytotoxicity of B4C-reinforced CoCrMo, Ti, and 17-4 PH alloys were systematically evaluated using human osteoblast (HOB) cells. Composites were fabricated via powder metallurgy with varying B4C reinforcement ratios (CoCrMo and Ti: 5–10 wt%; 17-4 PH: 3–12 wt%). Extracts prepared according to ISO 10993-12 standards were applied at different concentrations (100%, 50%, 25%, 12.5%) to assess cell viability using the MTT assay over 24, 48, and 72 h. Results demonstrated a clear dose-dependent cytotoxic effect across all composite systems. Ti composites exhibited the highest biocompatibility, with cell viability largely preserved even at higher B4C ratios. CoCrMo composites showed moderate cytotoxicity, which decreased upon extract dilution, indicating low-concentration compatibility. In contrast, 17-4 PH composites revealed significant cytotoxicity at higher extract concentrations, exacerbated by increasing B4C content. Literature-supported findings confirm that B4C incorporation enhances hardness, wear resistance, and elastic modulus, yet excessive reinforcement can induce local stress and particle detachment, affecting cellular tolerance. Diluted extracts of Ti and CoCrMo composites maintained cell viability at a biocompatible level consistent with ISO 10993-5 criteria. These results highlight the promising biocompatibility of B4C-reinforced Ti and CoCrMo alloys for biomedical applications and provide a biological basis for the design of next-generation composite implants.
Güder et al. (Sun,) studied this question.